(Yicai Global) Sept.13 -- Shanghai Ennopharm Co., a start-up focused on the research and development of anti-tumor drugs, has secured USD10 million (CNY65.1 million) in pre-A round financing led by HighLight Capital and Shanghai Zhangke Lingyi Investment Co.
The firm will use the funds to build a new drug research and development platform with a professional research team, startup service platform 6 Park said on Sept. 12.
Shanghai Ennopharm is a high-tech enterprise focused on the research and development of a new type of drug. It was founded by a team of researchers and developers through China's Thousands Talent Plan, which aims to bring foreign experts into China.
The company's founder Jiang Lei previously worked at Novartis AG [NYSE:NVS], a large pharmaceutical firm, where he focused on the research and development of new anti-cancer drugs. Jiang led a number of new targeted drugs research projects with several making it clinical studies.
Shanghai Ennopharm was founded in December 2016 and has focused on the field of refractory tumors since its establishment. In less than a year it has set up a strategy-based new anti-tumor drugs platform for research and development. The firm aims to overcome tumor drug resistance and increase patient benefits.